Zealand Pharma completes enrollment in ZUPREME-1 trial
Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...
Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
The Manila Times8h
Transaction in Own Shares
No ordinary shares are held in treasury. Therefore, the total number of voting rights in the Company is 369,545,021.
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...